

## EQA round: APLA2/22 - Antiphospholipid Antibodies

Key: >>> ... marks correct (expected) result  
> ... marks conditionally correct (acceptable) result  
± ... marks the result not evaluated

N ... number of the results  
Nrel ... relative number of the results

## Test

Sample	Group	N	Result	N <sub>rel</sub>
<b>(461) anti-cardiolipin screening</b>				
A	All results	>>> 16	Positive	100 %
Total per sample: n = 16		Success: 100 %		
B	All results	>>> 16	Positive	100 %
Total per sample: n = 16		Success: 100 %		
Total success: 100 %				
<b>(463) anti-cardiolipin IgG</b>				
A	All results	1 Negative		1,6 %
		>>> 63 Positive		98 %
Total per sample: n = 64		Success: 98 %		
B	All results	1 Negative		1,6 %
		>>> 63 Positive		98 %
Total per sample: n = 64		Success: 98 %		
Total success: 98 %				
<b>(464) anti-cardiolipin IgM</b>				
A	All results	>>> 63	Negative	100 %
Total per sample: n = 63		Success: 100 %		
B	All results	>>> 63	Negative	100 %
Total per sample: n = 63		Success: 100 %		
Total success: 100 %				
<b>(465) anti-beta2-GP 1 screening</b>				
A	All results	>>> 14	Positive	100 %
Total per sample: n = 14		Success: 100 %		
B	All results	>>> 14	Positive	100 %
Total per sample: n = 14		Success: 100 %		
Total success: 100 %				
<b>(467) anti-beta2-GP 1 IgG</b>				
A	All results	>>> 60	Positive	100 %
Total per sample: n = 60		Success: 100 %		
B	All results	1 Negative		1,7 %
		>>> 59 Positive		98 %
Total per sample: n = 60		Success: 98 %		
Total success: 98 %				
<b>(468) anti-beta2-GP 1 IgM</b>				
A	All results	>>> 59	Negative	100 %
Total per sample: n = 59		Success: 100 %		
B	All results	>>> 59	Negative	100 %
Total per sample: n = 59		Success: 100 %		
Total success: 100 %				